ASXL1 Antibodies

Polycomb group protein ASXL1 (ASXL1)

Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG). Acts as coactivator of RARA and RXRA through association with NCOA1.

Acts as corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic part of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at'Lys-119' (H2AK119ub1).

Gene Information

Human
Gene Name:	ASXL1
Uniprot:	Q8IXJ9
Entrez:	171023

Family

Belongs to:
Asx family

Alternative Names

additional sex combs like 1 (Drosophila)

Molecular Weight

Mass (kDA):
165.432 kDA

Genomic Context

Human
Location:	20q11.21
Sequence:	20; NC_000020.11 (32358062..32439319)

Tissue Specificity

Widely expressed at low level. Expressed in heart, brain, skeletal muscle, placenta, pancreas, spleen, prostate, small intestine, colon, peripheral blood, leukocytes, bone marrow and fetal liver. Highly expressed in testes.

Subcellular Localizations

Nucleus.

Diseases

• Leukemia
• Myeloid Leukemia
• Leukemia, Myelocytic, Acute
• Neoplasms
• Dysmyelopoietic Syndromes
• Malignant Neoplasms
• Myeloproliferative Disease
• Thrombocytosis
• Primary Myelofibrosis
• Thrombocythemia, Essential
• Leukemia, Myelomonocytic, Chronic
• Polycythemia Vera

• Myelomonocytic Leukemia
• Polycythemia
• Cytogenetic Abnormality
• Cell Transformation, Neoplastic
• Myelodysplastic-myeloproliferative Diseases
• Myeloid Leukemia, Chronic
• Dysplasia

Interacting Proteins

• AKT1
• BAP1
• EED
• ESR1
• EZH2

• Rxra

Pathways

• Pathogenesis
• Methylation
• Dna Methylation
• Histone Modification
• Regulation Of Gene Expression
• Cell Proliferation
• Metaphase
• Cell Cycle
• Chromatin Remodeling
• Localization

• Rna Splicing
• Drug Resistance
• Mrna Splicing
• Viral Replication
• Oncogenesis

PTMs

• Methylation
• Demethylation

• Phosphorylation
• Hydroxylation

• Acetylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ASXL1

Best Uses Of The ASXL1 Marker

Flow cytometry can be employed in many areas of science. Cells or particles are the subject of the experiment, and antibodies can detect these molecules. Boster has high affinity primary antibodies, both polyclonal and monoclonal, that have been mentioned over the past 25 years and continue to be frequently referenced today. We'll be discussing a selection of primary antibodies from Boster in this article.

His research

His work on the ASXL1 marker has proved very influential in the development of an innovative treatment for a patient with asthma in a particular form. He found that ASXL1MT is monoubiquitinated, which makes it more stable. Furthermore, ASXL1MT's monoubiquitination improves its capacity to autodeubiquitinate. These results suggest that monoubiquitination could increase ASXL1MT's ability stay in the nucleus.

ASXL1 also interacts with EED BAP1, EZH2, & BAP1 which are vital for chromatin separation. This marker is responsible for promoting trimethylation H3 at Lysine 27, also known as H3K27me3. ASXL1 could act as an epigenetic scaffold that regulates various histone modifications. The researchers are now trying to determine exactly how ASXL1 functions in leukemia.

His primary antibodies

His primary antibodies were used to detect ASXL1 Aa1-587. The antibodies were created to detect His proteins in complexes, which allows them to recognize His protein that is rich in DNA. The ASXL1 aa1-587 marker is a compound that is present on histone H3 as well as histone H4. It was discovered that ASXL1 was involved in the recruitment of PcG proteins to chromatin and that these proteins played a role in inhibiting transcription of genes. The recruitment of transcriptional effectors may be assisted by the ASXL1 protein.

The ASXL1 model is a potent platform to test therapeutic compounds that target ASXL1 mutations that cause truncation in myeloid cancers. This approach enables researchers to discover new therapeutic compounds that can affect the underlying cellular mechanisms that are responsible for myeloid malignancies. ASXL1 is a key drug development target since it regulates a wide range of cells' processes.

ASXL1 mutations can be found in between 10 and 30 percent of myeloid tumors. MDS and AML suffer from poor prognosis due to mutations in ASXL1. Hematopoietic-specific deletions of ASXL1 result in progressive multi-lineage cytopenia and dysplasias. Mutated ASXL1 results is increased number of hematopoietic stem and hematopoietic cells.

This antibody may target DNA reactive EZH2 (a gene that alters the H3K27me2 level in human cells. ASXL1 is associated with the ASXL1 AAP loci in the PRC2. It also has a relationship with SUZ12 and EZH2, further confirming the existence protein-protein interactions. The co-immunoprecipitation studies were performed using benzonase, which ensured that the interaction was DNA-independent.

The ASXL1 knockdown cells showed a lower H3K27me3 content. ASXL1 loss is particularly evident in genes with dual H3K27me3 or H3K4me3 domains. This is in line with results of gene expression as well as the chromatin information. This study further confirms the notion that ASXL1 is a major regulator of H3K27me3 levels.